AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02993198 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carvedilol
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FACET JOINT UNDER CT GUIDANCE
Description: injection of triamcinolone in the facet joint under CT guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FACET JOINT UNDER CT GUIDANCE
Description: injection of triamcinolone in the facet joint under CT guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NERVE BLOCK UNDER CT GUIDANCE
Description: injection of triamcinolone around the dorsal ramus under CT guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NERVE BLOCK UNDER CT GUIDANCE
Description: injection of triamcinolone around the dorsal ramus under CT guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FACET JOINT UNDER FLUOROSCOPY GUIDANCE
Description: injection of triamcinolone in the facet joint under fluoroscopy guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FACET JOINT UNDER FLUOROSCOPY GUIDANCE
Description: injection of triamcinolone in the facet joint under fluoroscopy guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE
Description: injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NERVE BLOCK UNDER FLUOROSCOPY GUIDANCE
Description: injection of triamcinolone around the dorsal ramus under fluoroscopy guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: FACET JOINT UNDER ULTRASOUND GUIDANCE
Description: injection of triamcinolone in the facet joint under ultrasound guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: FACET JOINT UNDER ULTRASOUND GUIDANCE
Description: injection of triamcinolone in the facet joint under ultrasound guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: NERVE BLOCK UNDER ULTRASOUND GUIDANCE
Description: injection of triamcinolone around the dorsal ramus under ultrasound guidance
Study NCT03871192 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: NERVE BLOCK UNDER ULTRASOUND GUIDANCE
Description: injection of triamcinolone around the dorsal ramus under ultrasound guidance
Study NCT04253158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs.
Study NCT04253158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard and Harm prevention
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs increasing intentions to use harm prevention strategies.
Study NCT04253158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard and Expectancies
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and shifting alcohol-related expectancies.
Study NCT04253158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Expectancies and Harm prevention
Description: Behavioral intervention aimed at correcting erroneous norms about alcohol use and shifting alcohol-related expectancies.
Study NCT04253158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard and Normative perceptions
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs and correcting erroneous norms about alcohol use.
Study NCT04253158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normative perceptions and Harm prevention
Description: Behavioral intervention aimed at correcting erroneous norms about alcohol use and increasing intentions to harm prevention strategies.
Study NCT04253158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational standard, Normative Perceptions, and Expectancies
Description: Behavioral intervention aimed at increasing knowledge about alcohol and other drugs, correcting erroneous norms about alcohol use, and shifting alcohol-related expectancies.
Study NCT04253158 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Normative perceptions, Expectancies, and Harm Prevention
Description: Behavioral intervention aimed at correcting erroneous norms about alcohol use, shifting alcohol-related expectancies, and increasing intentions to use harm prevention strategies.
Study NCT02104895 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Accelerated partial breast irradiation (APBI)
Description: Accelerated partial breast irradiation (APBI) using intensity modulated radiotherapy (IMRT)
Study NCT02104895 — intervention group
Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Whole breast irradiation (WBI)
Description: Conventional whole breast irradiation (WBI)
Study NCT03538938 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: No Financial Incentives for Treatment Engagement
Description: No Financial Incentives for Treatment Engagement are offered.
Study NCT00655525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: fish oil
Description: 2.9 g of fish oil (2:1 EPA:DHA) administered orally every day for 3 months
Study NCT06350734 — intervention group
Intervention type: OTHER
Intervention: Non-Interventional Study
Description: Non-Interventional Study
Study NCT00655525 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo administered orally every day for 3 months
Study NCT04255953 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: behavioral telehealth
Description: Participants will receive 24 weekly group phone counseling sessions. Each session will last approximately 60 minutes and begin with an open-ended check-in question, followed by review of weekly self-monitoring data, question and answer time, and end with a new didactic topic of the week addressing diet, physical activity, or behavior change topics. Participants will be instructed to follow a diet that is reduced to 1200-1500 kcal/day and includes ≥ 5 fruit and vegetable (FV) servings per day, \<25% kcal from fat, and 20-30 g of fiber. Physical activity will be gradually increased through a guided home-based program. Throughout the intervention, self-monitoring will be emphasized as a key behavioral weight loss strategy.
Study NCT05150665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: En-masse retraction
Description: Power chain and Crimpable hook for En-Masse Retraction Retraction will start on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 200 g per side) extending between the crimpable hooks and the miniscrew
Study NCT04255953 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: behavioral telehealth
Description: Participants will receive 24 weekly group phone counseling sessions. Each session will last approximately 60 minutes and begin with an open-ended check-in question, followed by review of weekly self-monitoring data, question and answer time, and end with a new didactic topic of the week addressing diet, physical activity, or behavior change topics. Participants will be instructed to follow a diet that is reduced to 1200-1500 kcal/day and includes ≥ 5 fruit and vegetable (FV) servings per day, \<25% kcal from fat, and 20-30 g of fiber. Physical activity will be gradually increased through a guided home-based program. Throughout the intervention, self-monitoring will be emphasized as a key behavioral weight loss strategy.
Study NCT05150665 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Two step Retraction
Description: Retraction of canine started on a 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 150 g per side)followed by anterior teeth retraction on 0.017x0.025 Stainless steel wire using elastomeric chain (force applied will be 160 g per side) extending between the crimpable hooks and the mini-screw.
Study NCT04148547 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sooma transcranial direct current stimulation device
Description: This group received brain training through transcranial direct current for 20 minutes.
Study NCT04255953 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Treatment as Usual
Study NCT04148547 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Sooma transcranial direct current stimulation device
Description: This group received sham brain training through transcranial direct current for 20 minutes. The current is active for 15 seconds and then switches off until the intervention is finished.
Study NCT02329327 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Andexanet
Description: There were 2 possible dosing regimens: Low dose = 400 milligram (mg) bolus plus 4 mg/minute continuous infusion for 120 minutes; High dose = 800 mg bolus plus 8 mg/minute continuous infusion for 120 minutes.
Study NCT04560959 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: tACS
Description: tACS would be performed to epilepsy patients who have already received implantation of the SEEG electrodes
Study NCT00914225 — intervention group
Intervention type: OTHER
Intervention: Bednets and Water Purification
Description: Individuals in the intervention cohort will be provided with a LLIN and water filtration device. Subjects are followed for 24 months and have serial measurements of HIV disease progression. Data are collected every 3 months on the frequency of malaria, diarrhea and other co-morbidities, as well as compliance with LLIN and water filter use.
Study NCT00296855 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vasovist (BAY86-5283, MS-325)
Description: All patients receive a single IV bolus injection of Vasovist at a dose of 0,03 mmol/kg BW at a flowrate of 0,5 mL/sec, followed by a saline flush of at least 30 mL
Study NCT02473185 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Description: Cross-over
Study NCT02473185 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Methylphenidate
Description: Cross-over
Study NCT01374022 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ART Strategy
Description: Maximum alveolar recruitment maneuver in association with PEEP titrated by the static compliance of respiratory system.
Study NCT01374022 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ARDSNet Strategy
Description: Conventional mechanical ventilation strategy.
Study NCT01190813 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levodopa/Carbidopa
Description: Oral levodopa 0.76 mg/kg tid with carbidopa 0.17 mg/kg tid
Study NCT01190813 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral placebo tid
Study NCT01190813 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patching
Description: Two hours of daily patching
Study NCT01190813 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Patching
Description: Two hours of daily patching
Study NCT02539017 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Chemo
Description: Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
Study NCT02539017 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Chemo
Description: Epirubicin,75mg/m2,intravenous ,on day 1 of each 21 day cycle, 4 cycles Cyclophosphamide,0.6g/m2,intravenous, on day 1 of each 21 day cycle, 4 cycles Docetaxel,75mg/m2, intravenous, on day 1 of each 21 day cycle, 4 cycles
Study NCT02539017 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Immunotherapy
Description: Immunotherapy with double dendritic cell (DC)and cytokine-induced killer (CIK) cell
Study NCT02021214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylphenidate
Study NCT02021214 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study NCT02047279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: maze procedure
Description: The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases.
Study NCT02047279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: maze procedure
Description: The scheme of lesion pattern: box lesion + line to mitral valve + line from box to left atrial appendage. The ablation procedure was performed by using a dry bipolar radiofrequency ablation clamp. The left atrial appendage was excluded in all cases.
Study NCT02047279 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: mitral valve surgery
Description: For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
Study NCT01281839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: TMC435
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 24 or 48 weeks
Study NCT01281839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 150 mg capsule once daily for 12 weeks in addition to peginterferon alfa-2a and ribavirin for 48 weeks
Study NCT02047279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: mitral valve surgery
Description: For mitral regurgitation or stenosis, the procedures will be a valve repair in the majority of cases. For valves that are not amenable to repair, a valve replacement will be performed.
Study NCT01281839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Peginterferon alpha-2a (PegIFN alpha-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
Study NCT01281839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Peginterferon alpha-2a (PegIFN alpha-2a)
Description: One subcutaneous (under the skin) injection containing 0.5 mL solution with 180 mcg PegIFN alpha-2a once weekly for up to 48 weeks.
Study NCT01281839 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study NCT01281839 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ribavirin (RBV)
Description: 200-mg tablets of RBV (body-weight adjusted dose) taken orally (by mouth) twice daily for up to 48 weeks.
Study NCT01137578 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Ultrasound
Description: Ultrasounds to be performed on children with central venous catheters
Study NCT01137578 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Magnetic Resonance Imaging with Contrast
Description: Contrast-enhanced Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
Study NCT01137578 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: Magnetic Resonance Imaging without Contrast
Description: Magnetic Resonance Imaging (MRI) to be performed on children with central venous catheters
Study NCT04179916 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: stimulation in virtual reality
Description: HTC VIVE pro was used to stimulate patients in virtual reality. The glasses enable high resolution and high fluidity (90Hz) images to be displayed. The display used inside the glasses, OLED class, allows for accurate color replication. Numerous sensors placed in the glasses (such as gyroscope, accelerometer, magnetometer) supported by dedicated processors processing data from the sensors, instantly transfer the movement of the head of the rehabilitated person to virtual reality. Such a set allows to achieve full immersion in the virtual world. Various scenarios will be presented during the stimulation, such as beach, snow landscape, darkened room, rollercoaster ride.~It was planned to submit 3 scenarios with a total stimulation time of up to 20 minutes.
Study NCT04409171 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: oral glucose tolerance test
Study NCT02865512 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: thoracic epidural catheterization
Description: thoracic epidural catheterization for the management of postoperative pain
Study NCT04990011 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: BioXclude amnion chorion membrane
Description: The OAC will be closed by the Bioxclude ACM Amnion chorion membrane which is applied over the extraction socket then supported with a buccal advanced flap.
Study NCT04398823 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sclerosing foam of Lauromacrogol
Description: Participants in FS will receive enteroscopy with the sclerosing foam of lauromacrogol.
Study NCT04398823 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Sclersing liqiud of Lauromacrogol
Description: Participants in LS will receive enteroscopy with the sclerosing liquid of lauromacrogol.
Study NCT02199223 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: regorafenib + panitumumab
Study NCT01152814 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Seasonal flu vaccine
Description: This phase II is performed as a multicenters study site in elderly subjects. Enrolled subjects received one single IM dose of trivalent subunit inactivated adjuvanted flu vaccine during the vaccination visit, according to the study protocol (follow-up period: till day 22)
Study NCT01259089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib hydrochloride
Description: Given orally
Study NCT01259089 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hsp90 inhibitor AUY922
Description: Given IV
Study NCT01259089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laboratory biomarker analysis
Description: Correlative studies
Study NCT01259089 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: needle biopsy
Description: Undergo image-guided needle biopsy (correlative studies)
Study NCT01259089 — intervention group
Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: mutation analysis
Description: Correlative studies
Study NCT01259089 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: pharmacological study
Description: Correlative studies
Study NCT02229851 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
Study NCT02229851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: somapacitan
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration. Extension of 44 weeks' treatment following 8 weeks of titration.
Study NCT02229851 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: somatropin
Description: Administered subcutaneously (s.c., under the skin) once daily for 26 weeks following 8 weeks of titration. Re-randomisation to extension of 44 weeks' treatment following 8 weeks of titration.
Study NCT02229851 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: Administered subcutaneously (s.c., under the skin) once weekly for 26 weeks following 8 weeks of titration.
Study NCT02047279 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: left atrial reduction
Description: The enlarged left atria are plicated (suture technique) between the left and right pulmonary vein down to the inferior end of left atrial incision on the half-moon shape.
Study NCT02683980 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Lumenis Pulse P120H and Xpeeda side firing fiber
Study NCT01190085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: A 1 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Study NCT00853944 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sitagliptin
Description: Subjects receive sitagliptin 100 mg po daily from the day of islet transplant until completion of the study
Study NCT02632604 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Computerized cognitive training
Description: 40 hours of a computerized cognitive training, given 1 hour daily
Study NCT01190085 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ghrelin
Description: A 3 microg/kg dose of intravenous human acetylated ghrelin was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.
Study NCT01190085 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline solution
Description: Intravenous saline solution (matched placebo) was administered once approximately 10 minutes before the start of the alcohol cue-reactivity experiment.